Shots:

• Nemolizumab is a novel therapy targeting IL-31 receptor A developed utilizing Chugai’s antibody engineering technology ACT-Ig. The 8th BT designation is granted to the Chugai based on P-II clinical study conducted by Galderma and the results were presented at EADV 2019
• The BT designation is granted to serious or life-threatening disease therapies demonstrate a substantial improvement over existing therapies on one or more significant preliminary research endpoints
• Galderma is initiating the P-III trial for nemolizumab in adults with prurigo nodularis in 2020. In 2016- Chugai and Galderma signed a global license agreement for nemolizumab (CIM331)- a novel biologic for skin diseases

Click here ­to­ read full press release/ article | Ref: Chugai  | Image: Chugai